As of July 28, 2023, Precision BioSciences, a renowned company, has garnered attention from industry analyst Patrick Trucchio at HC Wainwright & Co. Notably, on June 1, 2023, HC Wainwright & Co. reaffirmed their coverage of Precision BioSciences, providing a favorable Buy recommendation. However, it is worth mentioning that they revised their price target, reducing it from $17 to $5.
Precision BioSciences, Inc.
Updated on: 04/12/2023
Debt to equity ratio: Strong Buy
Price to earnings ratio: Sell
Price to book ratio: Strong Buy
DCF: Strong Buy
ROE: Strong Sell
4:00 PM (UTC)
Date:01 December, 2023
|Analyst / firm||Rating|
DTIL Stock Performance on July 28, 2023: Stable Day with Positive Turnaround in Earnings
DTIL Stock Performance on July 28, 2023
On July 28, 2023, Precision BioSciences Inc. (DTIL) experienced a relatively stable day in terms of stock performance. The previous close for DTIL was $0.57, and the stock opened at $0.58. Throughout the day, the stock fluctuated within a range of $0.54 to $0.58. The volume for the day was 7,540 shares, which is significantly lower than the average volume of 701,108 shares over the past three months. The market capitalization for DTIL stands at $72.9 million.
In terms of earnings growth, DTIL had a challenging year, with a negative growth rate of -143.59% last year. However, there has been a positive turnaround this year, with earnings growth reaching +25.59%. Looking ahead, there is no available data on the projected earnings growth for the next five years.
The revenue growth for DTIL in the previous year was -78.28%, indicating a decline in sales. The P/E ratio for DTIL is not available (NM), suggesting that the company may not have positive earnings or that it is not applicable in this case. The price/sales ratio stands at 4.17, indicating that investors are willing to pay 4.17 times the company’s annual revenue for its stock. The price/book ratio is 1.18, which suggests that the stock is trading at a reasonable valuation based on the company’s book value.
DTIL’s next reporting date is scheduled for August 17, 2023. The EPS forecast for this quarter is -$0.25. In the previous year, DTIL generated $25.1 million in annual revenue but incurred a loss of -$111.6 million. The net profit margin for the company stands at -444.80%, indicating significant losses.
DTIL operates in the Health Technology sector, specifically in the Biotechnology industry. Unfortunately, there is no available information on the company’s executives. The corporate headquarters of DTIL is located in Durham, North Carolina.
In conclusion, DTIL had a relatively stable day on July 28, 2023, with a small increase in stock price. The company has experienced significant challenges in terms of earnings and revenue growth in the past, but there has been some improvement in the current year. Investors should closely monitor the company’s performance and upcoming earnings report to assess its future prospects.
DTIL Stock Performance on July 28, 2023: Promising Signs and Potential 444.96% Increase in Median Target Price
DTIL (Precision BioSciences Inc) Stock Performance on July 28, 2023
On July 28, 2023, the stock performance of DTIL showed promising signs, with a median target price forecasted to increase by 444.96% from its last recorded price.
According to data sourced from CNN Money, six analysts have provided 12-month price forecasts for DTIL, with a median target price of $3.00. The high estimate stands at $17.00, while the low estimate is $1.00.
The current consensus among the six polled investment analysts is to buy stock in Precision BioSciences Inc. This rating has remained steady since June.
DTIL reported an earnings per share of -$0.25 for the current quarter. The sales for the quarter were reported at $6.4 million.
Investors should keep an eye on DTIL’s upcoming reporting date, which is scheduled for August 17.
Overall, the stock performance of DTIL on July 28, 2023, appears promising. However, it is important for investors to conduct their own research and consider the inherent risks associated with investing in the biotechnology sector.